Avoro Capital Advisors
$11.1B 13F equity value
32 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Avoro Capital Advisors covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| UTHR | UNITED THERAPEUTICS CORP | 2,777,777 | $1.5B | 13.5% |
| ASND | ASCENDIS PHARMA | 5,111,111 | $1.4B | 12.2% |
| KRYS | KRYSTAL BIOTECH INC | 2,888,888 | $1.1B | 9.6% |
| MDGL | MADRIGAL PHARMACEUTICALS INC | 1,833,333 | $984M | 8.8% |
| ARGX | ARGENX SE | 1,000,000 | $928M | 8.3% |
| ARWR | ARROWHEAD PHARMACEUTICALS INC | 11,355,555 | $926M | 8.3% |
| KYMR | KYMERA THERAPEUTICS INC | 7,474,747 | $857M | 7.7% |
| RVMD | REVOLUTION MEDICINES INC | 2,297,000 | $430M | 3.9% |
| CYTK | CYTOKINETICS INC | 4,999,999 | $426M | 3.8% |
| CELC | CELCUITY INC | 3,400,000 | $356M | 3.2% |
Track Avoro Capital Advisors's 13F portfolio: $11.1B in reported holdings, 32 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}